These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 34565600)

  • 1. Clinical outcome in patients with primary epithelial ovarian cancer and germline BRCA1/2-mutation - real life data.
    Ataseven B; Tripon D; Schwameis R; Harter P; Rhiem K; Schneider S; Heikaus S; Baert T; Francesco AP; Heitz F; Traut A; Groeben HT; Schmutzler R; du Bois A
    Gynecol Oncol; 2021 Dec; 163(3):569-577. PubMed ID: 34565600
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Incidence of germline BRCA1/2 mutations in women with tubo-ovarian high-grade serous carcinomas with and without serous tubal intra-epithelial carcinomas.
    Dowson CB; Stewart C; O'Sullivan S; Pachter N; Schofield L; Cohen PA
    Int J Gynecol Cancer; 2020 Jan; 30(1):94-99. PubMed ID: 31699802
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The first Japanese nationwide multicenter study of
    Enomoto T; Aoki D; Hattori K; Jinushi M; Kigawa J; Takeshima N; Tsuda H; Watanabe Y; Yoshihara K; Sugiyama T
    Int J Gynecol Cancer; 2019 Jul; 29(6):1043-1049. PubMed ID: 31263023
    [TBL] [Abstract][Full Text] [Related]  

  • 4. BRCA mutational status, initial disease presentation, and clinical outcome in high-grade serous advanced ovarian cancer: a multicenter study.
    Petrillo M; Marchetti C; De Leo R; Musella A; Capoluongo E; Paris I; Benedetti Panici P; Scambia G; Fagotti A
    Am J Obstet Gynecol; 2017 Sep; 217(3):334.e1-334.e9. PubMed ID: 28549976
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Germline and Somatic BRCA1/2 Gene Mutational Status and Clinical Outcomes in Epithelial Peritoneal, Ovarian, and Fallopian Tube Cancer: Over a Decade of Experience in a Single Institution in Korea.
    Kim SI; Lee M; Kim HS; Chung HH; Kim JW; Park NH; Song YS
    Cancer Res Treat; 2020 Oct; 52(4):1229-1241. PubMed ID: 32718143
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinicopathological features of women with epithelial ovarian cancer and double heterozygosity for BRCA1 and BRCA2: A systematic review and case report analysis.
    Le Page C; Rahimi K; Rodrigues M; Heinzelmann-Schwarz V; Recio N; Tommasi S; Bataillon G; Portelance L; Golmard L; Meunier L; Tonin PN; Gotlieb W; Yasmeen A; Ray-Coquard I; Labidi-Galy SI; Provencher D; Mes-Masson AM
    Gynecol Oncol; 2020 Feb; 156(2):377-386. PubMed ID: 31753525
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Survival Benefit of Germline BRCA Mutation is Associated with Residual Disease in Ovarian Cancer.
    Shi T; Wang P; Tang W; Jiang R; Yin S; Shi D; Wang Q; Wei Q; Zang R
    Cell Physiol Biochem; 2018; 47(5):2088-2096. PubMed ID: 29975922
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prevalence and clinical characterization of BRCA1 and BRCA2 mutations in Korean patients with epithelial ovarian cancer.
    Paik ES; Heo EJ; Choi CH; Kim JH; Kim JW; Kim YM; Park SY; Lee JW; Kim JW; Kim BG
    Cancer Sci; 2021 Dec; 112(12):5055-5067. PubMed ID: 34657357
    [TBL] [Abstract][Full Text] [Related]  

  • 9. BRCA1 and BRCA2 mRNA-expression prove to be of clinical impact in ovarian cancer.
    Tsibulak I; Wieser V; Degasper C; Shivalingaiah G; Wenzel S; Sprung S; Lax SF; Marth C; Fiegl H; Zeimet AG
    Br J Cancer; 2018 Sep; 119(6):683-692. PubMed ID: 30111871
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinicopathological characterization of a real-world multicenter cohort of endometrioid ovarian carcinoma: Analysis of the French national ESME-Unicancer database.
    De Nonneville A; Zemmour C; Frank S; Joly F; Ray-Coquard I; Costaz H; Classe JM; Floquet A; De la Motte Rouge T; Colombo PE; Sauterey B; Leblanc E; Pomel C; Marchal F; Barranger E; Savoye AM; Guillemet C; Petit T; Pautier P; Rouzier R; Gladieff L; Simon G; Courtinard C; Sabatier R
    Gynecol Oncol; 2021 Oct; 163(1):64-71. PubMed ID: 34294414
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic factors value of germline and somatic brca in patients undergoing surgery for recurrent ovarian cancer with liver metastases.
    Gallotta V; Conte C; D'Indinosante M; Capoluongo E; Minucci A; De Rose AM; Ardito F; Giuliante F; Di Giorgio A; Zannoni GF; Fagotti A; Margreiter C; Scambia G; Ferrandina G
    Eur J Surg Oncol; 2019 Nov; 45(11):2096-2102. PubMed ID: 31227342
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Outcome of BRCA1- compared with BRCA2-associated ovarian cancer: a nationwide study in the Netherlands.
    Vencken PM; Reitsma W; Kriege M; Mourits MJ; de Bock GH; de Hullu JA; van Altena AM; Gaarenstroom KN; Vasen HF; Adank MA; Schmidt MK; van Beurden M; Zweemer RP; Rijcken F; Slangen BF; Burger CW; Seynaeve C
    Ann Oncol; 2013 Aug; 24(8):2036-42. PubMed ID: 23543211
    [TBL] [Abstract][Full Text] [Related]  

  • 13. BRCA1/2 in non-mucinous epithelial ovarian cancer: tumour with or without germline testing?
    Morgan RD; Burghel GJ; Flaum N; Bulman M; Smith P; Clamp AR; Hasan J; Mitchell CL; Salih Z; Woodward ER; Lalloo F; Crosbie EJ; Edmondson RJ; Wallace AJ; Jayson GC; Evans DGR
    Br J Cancer; 2022 Jul; 127(1):163-167. PubMed ID: 35260807
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prevalence of pathogenic BRCA1/2 germline mutations among 802 women with unilateral triple-negative breast cancer without family cancer history.
    Engel C; Rhiem K; Hahnen E; Loibl S; Weber KE; Seiler S; Zachariae S; Hauke J; Wappenschmidt B; Waha A; Blümcke B; Kiechle M; Meindl A; Niederacher D; Bartram CR; Speiser D; Schlegelberger B; Arnold N; Wieacker P; Leinert E; Gehrig A; Briest S; Kast K; Riess O; Emons G; Weber BHF; Engel J; Schmutzler RK;
    BMC Cancer; 2018 Mar; 18(1):265. PubMed ID: 29514593
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The role of BRCA status on the prognosis of patients with epithelial ovarian cancer: a systematic review of the literature with a meta-analysis.
    Sun C; Li N; Ding D; Weng D; Meng L; Chen G; Ma D
    PLoS One; 2014; 9(5):e95285. PubMed ID: 24788697
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Predicting the likelihood of a
    Morgan RD; Burghel GJ; Flaum N; Bulman M; Smith P; Clamp AR; Hasan J; Mitchell C; Salih Z; Woodward ER; Lalloo F; Shaw J; Desai S; Crosbie EJ; Edmondson RJ; Schlecht H; Wallace AJ; Jayson GC; Evans DGR
    J Clin Pathol; 2023 Oct; 76(10):684-689. PubMed ID: 35738887
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of Clinical Features and Outcomes in Epithelial Ovarian Cancer according to Tumorigenicity in Patient-Derived Xenograft Models.
    Eoh KJ; Chung YS; Lee SH; Park SA; Kim HJ; Yang W; Lee IO; Lee JY; Cho H; Chay DB; Kim S; Kim SW; Kim JH; Kim YT; Nam EJ
    Cancer Res Treat; 2018 Jul; 50(3):956-963. PubMed ID: 29059719
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The correlation between BRCA status and surgical cytoreduction in high-grade serous ovarian carcinoma.
    Kim SR; Malcolmson J; Li X; Bernardini MQ; Hogen L; May T
    Gynecol Oncol; 2021 Sep; 162(3):702-706. PubMed ID: 34256977
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Association between family history, mutation locations, and prevalence of BRCA1 or 2 mutations in ovarian cancer patients.
    Singer CF; Tan YY; Muhr D; Rappaport C; Gschwantler-Kaulich D; Grimm C; Polterauer S; Pfeiler G; Berger A; Tea MM
    Cancer Med; 2019 Apr; 8(4):1875-1881. PubMed ID: 30821131
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prevalence of Pathogenic Germline
    Abe A; Imoto I; Tange S; Nishimura M; Iwasa T
    Genes (Basel); 2022 Jun; 13(6):. PubMed ID: 35741847
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.